MX370818B - Anticuerpos anti-b7-h1 para tratar tumores. - Google Patents

Anticuerpos anti-b7-h1 para tratar tumores.

Info

Publication number
MX370818B
MX370818B MX2016002826A MX2016002826A MX370818B MX 370818 B MX370818 B MX 370818B MX 2016002826 A MX2016002826 A MX 2016002826A MX 2016002826 A MX2016002826 A MX 2016002826A MX 370818 B MX370818 B MX 370818B
Authority
MX
Mexico
Prior art keywords
antibodies
treating tumors
treating
tumors
medi4736
Prior art date
Application number
MX2016002826A
Other languages
English (en)
Other versions
MX2016002826A (es
Inventor
Roskos Lorin
Rebelatto Marlon
Fairman David
Narwal Rajesh
Robbins Paul
Liang Meina
SCHNEIDER Amy
Chavez Carlos
Herl Carina
PAK Min
Lu Hong
Steele Keith
Boutrin Anmarie
Shi Li
Hong Shengyan
Higgs Brandon
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of MX2016002826A publication Critical patent/MX2016002826A/es
Publication of MX370818B publication Critical patent/MX370818B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70532—B7 molecules, e.g. CD80, CD86

Abstract

La presente invención se refiere a un MEDI4736 o un fragmento de unión a antígeno del mismo para usarse en el tratamiento de un paciente identificado que tiene un carcinoma de pulmón de células no pequeñas (NSCLC) positivo par PD-L1, en donde el MEDI4736 o un fragmento de unión a antígeno del mismo está adaptado para ser administrable al paciente en 10 mg/kg cada dos semanas o cada tres semanas.
MX2016002826A 2013-09-11 2014-09-11 Anticuerpos anti-b7-h1 para tratar tumores. MX370818B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361876509P 2013-09-11 2013-09-11
US201461971212P 2014-03-27 2014-03-27
US201461978401P 2014-04-11 2014-04-11
US201462003349P 2014-05-27 2014-05-27
PCT/EP2014/069425 WO2015036499A1 (en) 2013-09-11 2014-09-11 Anti-b7-h1 antibodies for treating tumors

Publications (2)

Publication Number Publication Date
MX2016002826A MX2016002826A (es) 2016-09-13
MX370818B true MX370818B (es) 2020-01-08

Family

ID=51570487

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016002826A MX370818B (es) 2013-09-11 2014-09-11 Anticuerpos anti-b7-h1 para tratar tumores.

Country Status (19)

Country Link
US (3) US10336823B2 (es)
EP (2) EP3656398A1 (es)
JP (5) JP6550053B2 (es)
KR (4) KR20210143932A (es)
CN (2) CN112546217A (es)
AU (2) AU2014320343B2 (es)
BR (1) BR112016005303A2 (es)
CA (1) CA2923499A1 (es)
DK (1) DK3043816T3 (es)
ES (1) ES2749744T3 (es)
HU (1) HUE046674T2 (es)
IL (3) IL244422B (es)
MX (1) MX370818B (es)
NZ (2) NZ757060A (es)
PL (1) PL3043816T3 (es)
RU (1) RU2701327C2 (es)
SA (1) SA516370713B1 (es)
TW (1) TWI643633B (es)
WO (1) WO2015036499A1 (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201507333XA (en) 2013-03-15 2015-10-29 Genentech Inc Biomarkers and methods of treating pd-1 and pd-l1 related conditions
CA2923499A1 (en) 2013-09-11 2015-03-19 Medimmune Limited Anti-pd-l1 antibodies for treating non-small cell lung carcinoma (nsclc)
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
SG11201609468WA (en) * 2014-05-29 2016-12-29 Medimmune Ltd Antagonists of pdl-1 and pd-1 for the treatment of hpv-negative cancers
JP6666905B2 (ja) 2014-05-29 2020-03-18 スプリング バイオサイエンス コーポレーション Ｐｄ−ｌ１抗体及びその使用
MY188940A (en) 2014-07-11 2022-01-13 Ventana Med Syst Inc Anti-pd-l1 antibodies and diagnostic uses thereof
US20170275347A1 (en) * 2014-09-05 2017-09-28 Medimmune Limited Methods for identifying patients responsive to anti-pd-l1 antibody therapy
US11344620B2 (en) 2014-09-13 2022-05-31 Novartis Ag Combination therapies
PE20171067A1 (es) 2014-10-14 2017-07-24 Novartis Ag Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas
WO2016124558A1 (en) 2015-02-03 2016-08-11 Ventana Medical Systems, Inc. Histochemical assay for evaluating expression of programmed death ligand 1 (pd-l1)
EP3262073A1 (en) 2015-02-26 2018-01-03 Merck Patent GmbH Pd-1 / pd-l1 inhibitors for the treatment of cancer
WO2016149201A2 (en) 2015-03-13 2016-09-22 Cytomx Therapeutics, Inc. Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
KR20170139071A (ko) * 2015-04-23 2017-12-18 메디뮨 리미티드 Egfr 돌연변이에 대해 양성인 비소세포 폐암의 조합 치료
HUE051815T2 (hu) 2015-05-12 2021-03-29 Hoffmann La Roche Terápiás és diagnosztikai eljárások rákra
US10696745B2 (en) 2015-06-11 2020-06-30 Wuxi Biologics (Shanghai) Co. Ltd. Anti-PD-L1 antibodies
IL256245B (en) 2015-06-16 2022-09-01 Merck Patent Gmbh Treatments that combine a pd-l1 antagonist
US20180340025A1 (en) 2015-07-29 2018-11-29 Novartis Ag Combination therapies comprising antibody molecules to lag-3
EP3316902A1 (en) 2015-07-29 2018-05-09 Novartis AG Combination therapies comprising antibody molecules to tim-3
WO2017020291A1 (en) 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
WO2017106656A1 (en) 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
CN106939047B (zh) * 2016-01-04 2021-08-31 江苏怀瑜药业有限公司 一种pd-l1抗体及其制备方法
WO2017176565A1 (en) 2016-04-07 2017-10-12 Eli Lilly And Company Combinations of an anti-b7-h1 antibody and a cxcr4 peptide antagonist for treating a solid tumor
WO2017202744A1 (en) * 2016-05-26 2017-11-30 Merck Patent Gmbh Pd-1 / pd-l1 inhibitors for cancer treatment
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
JP6910653B2 (ja) * 2016-07-01 2021-07-28 国立大学法人東北大学 免疫チェックポイント阻害薬使用における免疫関連副作用の予測方法
KR20190062515A (ko) 2016-10-06 2019-06-05 화이자 인코포레이티드 암의 치료를 위한 아벨루맙의 투약 용법
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
US11168144B2 (en) 2017-06-01 2021-11-09 Cytomx Therapeutics, Inc. Activatable anti-PDL1 antibodies, and methods of use thereof
KR20200078481A (ko) 2017-08-18 2020-07-01 아다스트라 파마수티컬스, 인코포레이티드 Tg02의 다형성 형태
CN111971059A (zh) * 2018-01-31 2020-11-20 细胞基因公司 使用过继细胞疗法和检查点抑制剂的组合疗法
SG11202008802QA (en) * 2018-03-22 2020-10-29 Keires Ag Antagonistic pd-1, pd-l1 and lag-3 binding proteins
CN114269763A (zh) 2019-03-26 2022-04-01 美国密歇根州立大学试剂中心 Stat3的小分子降解剂
EP3947403A1 (en) 2019-03-29 2022-02-09 The Regents Of The University Of Michigan Stat3 protein degraders
EP3983084A1 (en) 2019-06-12 2022-04-20 Vanderbilt University Amino acid transport inhibitors and the uses thereof
EP3983377A1 (en) 2019-06-12 2022-04-20 Vanderbilt University Dibenzylamines as amino acid transport inhibitors
AU2020301417A1 (en) * 2019-06-25 2022-01-06 City Of Hope PDL1 positive NK cell cancer treatment
AU2020315401A1 (en) 2019-07-16 2022-02-17 The Regents Of The University Of Michigan Imidazopyrimidines as EED inhibitors and the use thereof
US20220388978A1 (en) 2019-08-27 2022-12-08 Regents Of The University Of Michigan Cereblon e3 ligase inhibitors
JP2022548775A (ja) 2019-09-19 2022-11-21 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン スピロ環式アンドロゲン受容体タンパク質分解剤
KR20220102609A (ko) * 2019-09-25 2022-07-20 우시 바이올로직스 아일랜드 리미티드 신규한 항-pd-l1 항체
US20230159573A1 (en) 2020-03-26 2023-05-25 The Regents Of The University Of Michigan Small molecule stat protein degraders
US20230233690A1 (en) 2020-07-10 2023-07-27 The Regents Of The University Of Michigan Androgen receptor protein degraders
US20230257365A1 (en) 2020-07-10 2023-08-17 The Regents Of The University Of Michigan Small molecule androgen receptor protein degraders
WO2022187423A1 (en) 2021-03-03 2022-09-09 The Regents Of The University Of Michigan Cereblon ligands
WO2022187419A1 (en) 2021-03-03 2022-09-09 The Regents Of The University Of Michigan Small molecule degraders of androgen receptor

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2192884C2 (ru) * 2000-11-09 2002-11-20 Государственное учреждение Научно-исследовательский институт клинической иммунологии СО РАМН Вакцина для стимуляции противоопухолевого иммунитета
US7794710B2 (en) * 2001-04-20 2010-09-14 Mayo Foundation For Medical Education And Research Methods of enhancing T cell responsiveness
US20100285039A1 (en) * 2008-01-03 2010-11-11 The Johns Hopkins University B7-H1 (CD274) Antagonists Induce Apoptosis of Tumor Cells
KR101050829B1 (ko) * 2008-10-02 2011-07-20 서울대학교산학협력단 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제
CN101693562A (zh) * 2009-10-21 2010-04-14 山东大学 一种聚合氯化铁-聚环氧氯丙烷-二甲胺复合混凝剂
SI3279215T1 (sl) * 2009-11-24 2020-07-31 Medimmune Limited Usmerjena vezavna sredstva proti B7-H1
WO2013079174A1 (en) * 2011-11-28 2013-06-06 Merck Patent Gmbh Anti-pd-l1 antibodies and uses thereof
US9856320B2 (en) * 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
CA2923499A1 (en) * 2013-09-11 2015-03-19 Medimmune Limited Anti-pd-l1 antibodies for treating non-small cell lung carcinoma (nsclc)
EP3142751B1 (en) * 2014-05-13 2019-08-07 MedImmune Limited Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small cell lung cancer
US10092645B2 (en) * 2014-06-17 2018-10-09 Medimmune Limited Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy
US20170275347A1 (en) * 2014-09-05 2017-09-28 Medimmune Limited Methods for identifying patients responsive to anti-pd-l1 antibody therapy
EP3220951A1 (en) * 2014-11-17 2017-09-27 MedImmune Limited Therapeutic combinations and methods for treating neoplasia
US20160347848A1 (en) * 2015-05-28 2016-12-01 Medimmune Limited Therapeutic combinations and methods for treating neoplasia
AU2017257505B2 (en) * 2016-04-25 2020-05-14 Medimmune, Llc Compositions comprising coformulation of anti-PD-L1 and Anti-CTLA-4 antibodies
CN109153729A (zh) * 2016-05-13 2019-01-04 免疫医疗有限责任公司 Cd40l-fc融合多肽及其使用方法

Also Published As

Publication number Publication date
CN105873606A (zh) 2016-08-17
TW201605472A (zh) 2016-02-16
IL274462A (en) 2020-06-30
EP3656398A1 (en) 2020-05-27
WO2015036499A1 (en) 2015-03-19
US10829557B2 (en) 2020-11-10
HUE046674T2 (hu) 2020-03-30
KR102329584B1 (ko) 2021-11-22
RU2016113341A3 (es) 2018-05-30
BR112016005303A2 (pt) 2017-09-12
JP2021006537A (ja) 2021-01-21
MX2016002826A (es) 2016-09-13
IL244422B (en) 2020-05-31
KR20240056664A (ko) 2024-04-30
AU2014320343B2 (en) 2020-05-28
NZ718821A (en) 2022-07-01
CA2923499A1 (en) 2015-03-19
SA516370713B1 (ar) 2019-03-10
KR20160044030A (ko) 2016-04-22
JP2023166474A (ja) 2023-11-21
KR102661249B1 (ko) 2024-04-25
NZ757060A (en) 2022-07-01
JP7119037B2 (ja) 2022-08-16
TWI643633B (zh) 2018-12-11
IL274462B (en) 2022-05-01
US20190338033A1 (en) 2019-11-07
EP3043816A1 (en) 2016-07-20
JP2016530323A (ja) 2016-09-29
AU2020223728B2 (en) 2024-03-07
JP2019163269A (ja) 2019-09-26
IL244422A0 (en) 2016-04-21
US11827706B2 (en) 2023-11-28
RU2016113341A (ru) 2017-10-16
IL292193A (en) 2022-06-01
JP6550053B2 (ja) 2019-07-24
KR20220162843A (ko) 2022-12-08
US20160222120A1 (en) 2016-08-04
US20210171639A1 (en) 2021-06-10
DK3043816T3 (da) 2019-10-14
JP7342167B2 (ja) 2023-09-11
EP3043816B1 (en) 2019-08-14
CN112546217A (zh) 2021-03-26
JP2022065100A (ja) 2022-04-26
CN105873606B (zh) 2020-12-29
AU2020223728A1 (en) 2020-09-17
RU2019128452A (ru) 2019-10-24
KR20210143932A (ko) 2021-11-29
ES2749744T3 (es) 2020-03-23
AU2014320343A1 (en) 2016-04-21
PL3043816T3 (pl) 2020-03-31
US10336823B2 (en) 2019-07-02
RU2701327C2 (ru) 2019-09-25

Similar Documents

Publication Publication Date Title
MX2016002826A (es) Anticuerpos anti-b7-h1 para tratar tumores.
CY1122642T1 (el) Αντι-β7-η1 και anti-ctla-4 αντισωματα για τη θεραπευτικη αγωγη μη μικροκυτταρικου πνευμονικου καρκινου
HK1244293A1 (zh) 用cd3xcd20雙特異性抗體治療腫瘤的方法
GEP20217331B (en) Anti-tigit antibodies
PH12017500229A1 (en) Combination therapies with anti cd40 antibodies
HK1219486A1 (zh) 用於治療癌症的涉及抗密蛋白 的抗體的療法
MX2021002728A (es) Combinacion de anticuerpos anti-gen 3 de la activacion del linfoncito (lag-3) y anticuerpos anti-muerte celular programada 1 (pd-1) para usarse en el tratamiento de tumores.
HK1213925A1 (zh) 用於治療癌症的涉及抗密蛋白 抗體的組合療法
GEP20227343B (en) Anti-lag3 antibodies and antigen-binding fragments
EA201791208A1 (ru) Антитела к cd38 для лечения острого миелолейкоза
NZ710929A (en) Antibody drug conjugates
MX2016004570A (es) Uso de inhibidores del bromodominio de cbp/ep300 para la inmunoterapia del cáncer.
PH12016501366A1 (en) Novel anti-baff antibodies
IN2014DN05885A (es)
SI2976360T1 (sl) Terapija, ki vključuje protitelesa proti Klavdinu 18.2 za zdravljenje raka
RS63738B1 (sr) Kombinovana terapija koja uključuje antitela protiv klaudina 18.2 za lečenje kancera

Legal Events

Date Code Title Description
FG Grant or registration